Compare SHO & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHO | VIR |
|---|---|---|
| Founded | 1995 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 2004 | 2019 |
| Metric | SHO | VIR |
|---|---|---|
| Price | $10.80 | $8.96 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | $9.79 | ★ $19.43 |
| AVG Volume (30 Days) | ★ 2.5M | 1.5M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.66% | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $1,115,167,000.00 | $68,556,000.00 |
| Revenue This Year | $3.95 | $270.22 |
| Revenue Next Year | $2.30 | N/A |
| P/E Ratio | $48.36 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.69 | $4.25 |
| 52 Week High | $12.07 | $11.66 |
| Indicator | SHO | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 32.94 | 47.39 |
| Support Level | $8.82 | $8.43 |
| Resistance Level | $12.01 | $10.10 |
| Average True Range (ATR) | 0.27 | 0.41 |
| MACD | -0.13 | 0.01 |
| Stochastic Oscillator | 12.69 | 41.14 |
Sunstone Hotel Investors Inc is a real estate investment trust that acquires, owns, manages, and renovates the full-service hotel and select-service hotel properties across various states in the United States. Its firm's portfolio consists upper upscale and luxury hotels located in convention, resort destination and urban markets. Its majority of the hotels operate under a brand owned by Marriott, Hilton, Hyatt, Four Seasons or Montage. It operates geographically in California which generates the majority of its revenue; Florida; and Hawaii. The company's sole source of income is hotel revenue from its Hotel Ownership Segment.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.